Dr. Li has 30+ years of hands-on research, regulatory, and management experience in Rx, OTC, and generic CMC product development for US, EU, and China markets. He worked at Allegan, Schering-Plough (now Merck), Wyeth (now Pfizer), Eisai, Frontage, GSK, and FDA prior to joining DataRevive. He had hands-on CMC product development experience with sterile and non-sterile products. He was formerly Director of Drug Delivery at Eisai, US, and Science Excellence Director at GSK Consumer Healthcare, China.    

From 2014 to 2019, Dr. Li was a Biopharmaceutics reviewer in the Division of Biopharmaceutics/Office of New Drug Products, CMC Drug Product reviewer in the Office of Lifecycle Products, and a 4-month assignment in the Office of Surveillance. In the Division of Biopharmaceutics, he reviewed the biopharmaceutics data in IND, NDA, and ANDA submissions, including bridging study data. In the Office of Surveillance, he drafted site dossiers for inspectors to help them focus on residual cGMP gaps and recurring quality issues in recent cGMP inspections. In-Office of Lifecycle Products, Dr. Li reviewed ophthalmic and injectable generic product submissions. He collaborated with the OGD Science team to develop guidance for complex ophthalmic generic products. He was a member of the Ophthalmic Product Working Group to discuss challenging review issues. 

His industrial experiences include: CMC product development from candidate selection to commercial launch, marketing communication by translating science into easy-to-understand language, evaluation of a broad range of drug delivery systems to solve developability challenges of new drugs, and lifecycle management of marketed products, and managing CRO & CMO. His industrial and FDA experiences allow him to understand the point of view of both sides on a particular issue.

Dr. Li holds an MS and Ph.D. degree in Pharmaceutics from the University of Wisconsin-Madison and a Bachelor degree in Chemistry from Hamilton College.